HomeAI · summaries
Storia in 2 fonti
Exelixis Provides 'A Highly Defensive Investment Profile:' Analyst - Exelixis (NASDAQ:EXEL)
Exelixis reported final STELLAR-303 data showing a survival trend for zanzalintinib combo in metastatic colorectal cancer patients.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
benzinga.com
Exelixis Provides 'A Highly Defensive Investment Profile:' Analyst - Exelixis (NASDAQ:EXEL)
Exelixis reported final STELLAR-303 data showing a survival trend for zanzalintinib combo in metastatic colorectal cancer patients.
- ·
endpoints.news
Exelixis' TKI falls short in colorectal cancer subgroup as FDA reviews approval in all-comers
Exelixis' zanzalintinib misses OS endpoint in mCRC subgroup without liver mets; FDA decision on all-comers approval due Dec 3.